Eva-Lotta Allan

Ms. Eva-Lotta Allan is a Non-Executive Chairman at Maxion Therapeutics Ltd., a Non-Executive Chairman at Draupnir Bio ApS and an Independent Non-Executive Director at Almirall SA. She is on the Board of Directors at Zelluna ASA, Almirall SA and Zelluna Immunotherapy AS.
Ms. Allan was previously employed as a Non-Executive Director by Aleta Biotherapeutics, Inc., a Non-Executive Chairman by C4X Discovery Holdings Ltd., a Non-Executive Director by Crescendo Biologics Ltd., an Independent Director by Targovax ASA, a Director & Chief Business Officer by Immunocore Holdings Ltd., a Chief Business Officer by Ablynx NV, a Senior Director-Global Business Development by Vertex Pharmaceuticals (Europe) Ltd., a Principal by GE Healthcare Ltd. (United Kingdom), a Principal by Karolinska Institutet, a Principal by Oxford Asymmetry International Plc, and a Principal by Oxford GlycoSciences Plc.
She also served on the board at Novavax AB and The Bioindustry Association.
She received her undergraduate degree from the University of Stockholm.